Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-18077
Mnich, C D; Hoek, K S; Oberholzer, P A; Seifert, Burkhardt; Hafner, J; Dummer, R; Mihic, D (2007). Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness. Melanoma Research, 17(2):131-136.
- Registered users only
View at publisher
Cutaneous melanoma is the most aggressive of cutaneous neoplasms. Identifying patients with an increased risk for the development of metastases is critical. This study investigates phospho-Smad2, a central factor of the transforming growth factor beta pathway, on formalin-fixed, paraffin-embedded tissues from 60 primary cutaneous melanomas (Breslow >1 mm), for its candidacy for being a prognostic marker in primary cutaneous melanoma. Phospho-Smad2 positivity was assessed for correlation with clinical parameters including Breslow index, melanoma type, survival, development of metastases, sentinel lymph node status and age. Phospho-Smad2 positivity was not associated with survival or development of metastases, suggesting that it would not be a useful prognostic marker. Despite this, we found phospho-Smad2 positivity to be correlated with low tumour thickness, indicating that as the primary tumour grows there is an increased inhibition of transforming growth factor beta signalling resulting in suppressed Smad2 phosphorylation. Additionally, phosphorylation of Smad2 in neighbouring melanoma cells and keratinocytes was interrelated, which is a further indication that Smad2 phosphorylation in primary melanoma is affected by local area microenvironmental factors. We hypothesize that the observed decrease in transforming growth factor beta signalling in thicker primary melanomas is due to the increased production of signalling inhibitors.
1 download since deposited on 08 Apr 2009
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology
04 Faculty of Medicine > Epidemology, Biostatistics and Prevention Institute (EBPI)
|DDC:||610 Medicine & health|
|Deposited On:||08 Apr 2009 09:18|
|Last Modified:||02 Oct 2014 13:06|
|Publisher:||Lippincott Wiliams & Wilkins|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page